In one paragraphArticle in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
David M DobrzynskiDivision of Infectious Diseases, Department of Medicine, University of Rochester, Rochester, New York, USA.ORCID 0000-0001-5652-7432 Daniel S GraciaaDivision of Infectious Diseases, Department of Medicine, Hope Clinic, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-9484-8488 Tara M BabuDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
Rhea N ColerSeattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle Children's, Seattle, Washington, USA.
Grant C PaulsenDepartment of Pediatrics, University of Cincinnati College of Medicine and Division of Pediatric Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.ORCID 0000-0002-8901-6513 Daniel F HoftDivision of Infectious Diseases, Allergy & Immunology, Center for Vaccine Development, Saint Louis University School of Medicine, Saint Louis University, St Louis, Missouri, USA.
Sharon E FreyDivision of Infectious Diseases, Allergy & Immunology, Center for Vaccine Development, Saint Louis University School of Medicine, Saint Louis University, St Louis, Missouri, USA.
Kathryn M EdwardsVanderbilt Vaccine Research Program, Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.ORCID 0000-0003-3912-9832 Wilbur H ChenCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-7741-5536 Funding
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2MVTEU SupplementUM1AI148689 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Karen L. Kotloff · 2020 to 2026
$52.7MVanderbilt Vaccine and Treatment Evaluation Unit - KidCOVEUM1AI148452 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Clarence Buddy Creech · 2020 to 2026
$51.3MVaccine and Treatment Evaluation Units - DMID 21-0012UM1AI148576 · NIAID · EMORY UNIVERSITY · PI Nadine Georges Rouphael, Carlos del Rio · 2020 to 2026
$41.7MVaccine and Treatment Evaluation Unit at Saint Louis University - DMID 20-0034UM1AI148685 · NIAID · SAINT LOUIS UNIVERSITY · PI Daniel F. Hoft · 2020 to 2026
$34.6MUniversity of Washington Vaccine and Treatment Evaluation Unit - DMID 21-0012UM1AI148573 · NIAID · UNIVERSITY OF WASHINGTON · PI Raymond Scott McClelland, Anna Wald · 2020 to 2026
$26.6MKaiser Washington VTEU supplement 20-0003UM1AI148373 · NIAID · KAISER FOUNDATION RESEARCH INSTITUTE · PI LISA A JACKSON · 2020 to 2026
$24.4MUniversity of Rochester Vaccine and Treatment Evaluation Unit (VTEU)-mRNA-1273-P204 Moderna Pediatric StudyUM1AI148450 · NIAID · UNIVERSITY OF ROCHESTER · PI Angela Ramona Branche, Ann R Falsey · 2020 to 2026
$20.6MCincinnati Children's Hospital Medical Center Vaccine and Treatment Evaluation Units (UM1 Clinical Trial Required) - Moderna Pediatric StudyUM1AI148372 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI Robert Wilson Frenck · 2020 to 2026
$20.5MEmory/Georgia TB Research Advancement Center (TRAC)P30AI168386 · NIAID · EMORY UNIVERSITY · PI Jeffrey M Collins · 2022 to 2026
$5.8MInfectious Diseases Clinical Research ConsortiumNational Institute of Allergy and Infectious DiseasesNIAID NIH HHS P30 AI168386NIAID NIH HHS UM1 AI148372NIAID NIH HHS UM1 AI148373NIAID NIH HHS UM1 AI148450NIAID NIH HHS UM1 AI148452NIAID NIH HHS UM1 AI148573NIAID NIH HHS UM1 AI148576NIAID NIH HHS UM1 AI148684NIAID NIH HHS UM1 AI148685NIAID NIH HHS UM1 AI148689NIH HHS UM1AI148684
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
global healthpandemic pathogensVaccine and Treatment Evaluation Unitvaccine platformsvaccinology
Identifiers
PMID41071740
PMCPMC12513350
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390